STOCK MARKET BSE NSE

DCGI rejects direct phase 3 trial of Sputnik V in India, asks for trial on smaller group first

The development comes less than a month after the Russian government announced its partnership with Dr Reddy’s Laboratories for mass vaccinations by the year-end.

Published: 07th October 2020 09:42 PM  |   Last Updated: 07th October 2020 09:42 PM   |  A+A-

Sputnik V, Russia covid-19 vaccine,

A new vaccine is on display at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia. (Photo | AP)

Express News Service

NEW DELHI: India’s apex drug regulator has rejected a proposal by pharmaceutical major Dr Reddy’s Laboratories to directly conduct phase 3 trial for Russian Covid-19 vaccine Sputnik V directly in India saying that the sample size for early human trials for the vaccine was “small”.

The regulator has now asked the Hyderabad-based firm, which has entered into a partnership with Russia for the local clinical trials and mass distribution of vaccine in India, to submit a revised proposal for phase 2 and 3 trials in the country.

A subject expert committee of the Drug Controller General of India, on Monday, in response to a proposal by the DRL noted that the safety and immunogenicity data in overseas phase 1 and 2 studies is “small” and insufficient for Indian subjects.

“After detailed deliberation, the committee recommended that the firm should follow the regulatory requirements and conduct phase 2/3 trial in the country with proper monitoring for humoral and cell mediated immune response,” the committee instructed.

It added that accordingly, the firm should submit the protocol for consideration of the committee.

Under the revised plan, the vaccine, which includes two adenovirus vectors, modified to express the SARS-CoV-2 spike protein, will have to be first assessed in a small group of volunteers to study its efficacy before it can be tested on a larger population.

The development comes less than a month after the Russian government announced its partnership with DRL for mass vaccinations by the year-end.

Under the plan, the Russian Direct Investment Fund which is leading the Covid-19 vaccine project in Russian plans to supply 100 million doses to Dr Reddy’s, upon regulatory approval.

Queries seeking responses from both Dr Reddy’s and the RDIF on the development remained unanswered.  

Sputnik V, which was found to be safe and effective in about 70 volunteers in Russia in phase 1 and 2 trials, as per a paper published in the Lancet, is currently under phase 3 trial involving 40,000 individuals. 

As per the details of the trials published, the vaccine induced antibody responses in all participants within 21 days.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology had been registered by the ministry of health of Russia and became the world’s first registered vaccine against Covid-19.

While announcing its partnership with DRL, RDIF had claimed that more than 55,000 volunteers had applied to take part in post-registration trials and the first results of these trials are expected to be published in October-November.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp